课题基金 / 基金详情

DOSE INTENSE MOPP FOR PATIENT WITH POOR PROGNOSIS HODGKINS DISEASE

DOSE INTENSE MOPP FOR PATIENT WITH POOR PROGNOSIS HODGKINS DISEASE
对预后不良的霍奇金病患者进行剂量强化 MOPP
批准号:
6123718
负责人:
B L GAUSE
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

B L GAUSE的其他基金

相似基金

相关文献

中文摘要
翻译
“该方案旨在治疗的子集
英文摘要
"This protocol was designed to treat the subset of Hodgkin's disease patients who are at highest risk for treatment failure. From the previous study of advanced Hodgkin's disease, we have identified patients with Stage IIIB, IVB, IVA (marrow) and massive mediastinal Hodgkin's disease as having lower response rates and survival. In order to improve the efficacy of MOPP therapy in this group of patients, the dose-intensity of all drugs has been increased and GM-CSF is given to ameliorate the severe myelotoxic effects of the increased drug doses. To date, 22 of 24 evaluable patients have achieved a complete response. Four patients have relapsed. One patient who was an induction failure has since undergone an allogeneic bone marrow transplant and achieved a complete response. The other induction failure underwent ABMT, achieved a CR, but relapsed after two months and died with progressive disease. Four patients have relapsed: one is in second CR following ABMT, one has relapsed following a short CR after ABMT; two others are currently receiving therapy. Twenty-three of 24 evaluable patients are alive: 21 free of disease, two with Hodgkin's disease. No unexpected toxicities have been observed with this treatment. This study is closed to accrual with follow-up continuing on non-relapsed patients."
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE I/II STUDY OF VACCINIA-HPV RECOMBINANT
OBSERVATION VS INTENSIVE CHEMOTHERAPY FOR INDOLENT LYMPHOMA
PHASE I/II STUDY OF VACCINIA-HPV RECOMBINANT
PHASE IA/B TRIAL OF ANTICD3 AND INTERLEUKIN 2
海外基金